Two-year outcomes of intravitreal aflibercept in a Swiss routine treat and extend regimen for patients with neovascular age-related macular degeneration
The aim of this observational study was to assess the use and outcome of intravitreal aflibercept in a treat and extend regimen in treatment-naïve neovascular AMD patients in routine practice. This both retrospective and prospective study was conducted in four larger Swiss retina clinics (ASTERIA st...
Gespeichert in:
| Veröffentlicht in: | Scientific reports 2020-11, Vol.10 (1), p.20256-20256, Article 20256 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 20256 |
|---|---|
| container_issue | 1 |
| container_start_page | 20256 |
| container_title | Scientific reports |
| container_volume | 10 |
| creator | Ebneter, Andreas Michels, Stephan Pruente, Christian Imesch, Pascal Eilenberger, Felix Oesch, Susanne Thomet-Hunziker, Isabelle P. Hatz, Katja |
| description | The aim of this observational study was to assess the use and outcome of intravitreal aflibercept in a treat and extend regimen in treatment-naïve neovascular AMD patients in routine practice. This both retrospective and prospective study was conducted in four larger Swiss retina clinics (ASTERIA study). The primary endpoint was the mean change in best-corrected visual acuity (BCVA) in ETDRS letters from baseline to 12 months. Between December 2017 and August 2018, 160 patients were included. For patients with available data, the mean change in BCVA was + 8.4 (± 14.4) letters at month 12 (n = 139) and + 5.0 (± 11.4) letters at month 24 (n = 95). A mean number of 8.3 (± 2.4) injections were administered within the first year and 5.4 (± 2.9) injections during the second year. On average, the observed treatment interval at month 12 was 63.3 (± 22.0) days and increased to 69.1 (± 28.6) days at month 24. For 37% of the patients, a treatment interval ≥ 12 weeks was attained at month 24. In conclusion, intravitreal aflibercept in a Swiss real-life treat and extend regimen resulted in comparable anatomic and functional outcomes as were observed in the prospective registration trials of aflibercept for nAMD treatment. |
| doi_str_mv | 10.1038/s41598-020-76354-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7680100</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2471575514</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-3d70bedc8d0e73195e3fc88a449910c2f4db30c77ee8f310d6ffb6e4fb6531743</originalsourceid><addsrcrecordid>eNp9UU1v1TAQjBAVrdr-AQ7IEhcuAX_GyQUJVVCQKnFoOVuOs05dJfbDdt5r_wk_F7-mlNIDPngt78zsjqaqXhP8nmDWfkiciK6tMcW1bJjgNXlRHVHMRU0ZpS-fvA-r05RucDmCdpx0r6pDxijpKKdH1a-rXajvQEcUlmzCDAkFi5zPUW9djqAnpO3keogGNrk0kEaXO5cSioXgPKA9KCPtBwS3GUqJMLoZPLIhoo3ODnxOaOfyNfIQtjqZZSrj9Ah1hElnGNCs178BRvAQCyf4k-rA6inB6UM9rn58-Xx19rW--H7-7ezTRW245Llmg8Q9DKYdMEhGOgHMmrbVnHcdwYZaPvQMGykBWssIHhpr-wZ4uQQjkrPj6uOqu1n6uQjB3vqkNtHNOt6poJ36t-PdtRrDVsmmxQTjIvDuQSCGnwukrGaXDEyTLnaXpChvylzeYFGgb59Bb8ISfbFXUJIIKQTZb0RXlIkhpQj2cRmC1T57tWavSvbqPntFCunNUxuPlD9JFwBbAam0_Ajx7-z_yP4GFMe-UA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2471575514</pqid></control><display><type>article</type><title>Two-year outcomes of intravitreal aflibercept in a Swiss routine treat and extend regimen for patients with neovascular age-related macular degeneration</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Springer Nature OA Free Journals</source><source>Nature Free</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><creator>Ebneter, Andreas ; Michels, Stephan ; Pruente, Christian ; Imesch, Pascal ; Eilenberger, Felix ; Oesch, Susanne ; Thomet-Hunziker, Isabelle P. ; Hatz, Katja</creator><creatorcontrib>Ebneter, Andreas ; Michels, Stephan ; Pruente, Christian ; Imesch, Pascal ; Eilenberger, Felix ; Oesch, Susanne ; Thomet-Hunziker, Isabelle P. ; Hatz, Katja</creatorcontrib><description>The aim of this observational study was to assess the use and outcome of intravitreal aflibercept in a treat and extend regimen in treatment-naïve neovascular AMD patients in routine practice. This both retrospective and prospective study was conducted in four larger Swiss retina clinics (ASTERIA study). The primary endpoint was the mean change in best-corrected visual acuity (BCVA) in ETDRS letters from baseline to 12 months. Between December 2017 and August 2018, 160 patients were included. For patients with available data, the mean change in BCVA was + 8.4 (± 14.4) letters at month 12 (n = 139) and + 5.0 (± 11.4) letters at month 24 (n = 95). A mean number of 8.3 (± 2.4) injections were administered within the first year and 5.4 (± 2.9) injections during the second year. On average, the observed treatment interval at month 12 was 63.3 (± 22.0) days and increased to 69.1 (± 28.6) days at month 24. For 37% of the patients, a treatment interval ≥ 12 weeks was attained at month 24. In conclusion, intravitreal aflibercept in a Swiss real-life treat and extend regimen resulted in comparable anatomic and functional outcomes as were observed in the prospective registration trials of aflibercept for nAMD treatment.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/s41598-020-76354-1</identifier><identifier>PMID: 33219242</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/308/409 ; 692/699/3161/1626 ; Acuity ; Age ; Angiogenesis Inhibitors - administration & dosage ; Angiogenesis Inhibitors - therapeutic use ; Clinical medicine ; Clinical trials ; Diabetic retinopathy ; Disease ; Ethics ; Humanities and Social Sciences ; Humans ; Intravitreal Injections ; Macular degeneration ; multidisciplinary ; Observational studies ; Receptors, Vascular Endothelial Growth Factor - administration & dosage ; Receptors, Vascular Endothelial Growth Factor - therapeutic use ; Recombinant Fusion Proteins - administration & dosage ; Recombinant Fusion Proteins - therapeutic use ; Registration ; Retina ; Science ; Science (multidisciplinary) ; Statistical analysis ; Switzerland ; Treatment Outcome ; Visual Acuity ; Wet Macular Degeneration - drug therapy ; Wet Macular Degeneration - physiopathology</subject><ispartof>Scientific reports, 2020-11, Vol.10 (1), p.20256-20256, Article 20256</ispartof><rights>The Author(s) 2020</rights><rights>The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-3d70bedc8d0e73195e3fc88a449910c2f4db30c77ee8f310d6ffb6e4fb6531743</citedby><cites>FETCH-LOGICAL-c474t-3d70bedc8d0e73195e3fc88a449910c2f4db30c77ee8f310d6ffb6e4fb6531743</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680100/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680100/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27903,27904,41099,42168,51555,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33219242$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ebneter, Andreas</creatorcontrib><creatorcontrib>Michels, Stephan</creatorcontrib><creatorcontrib>Pruente, Christian</creatorcontrib><creatorcontrib>Imesch, Pascal</creatorcontrib><creatorcontrib>Eilenberger, Felix</creatorcontrib><creatorcontrib>Oesch, Susanne</creatorcontrib><creatorcontrib>Thomet-Hunziker, Isabelle P.</creatorcontrib><creatorcontrib>Hatz, Katja</creatorcontrib><title>Two-year outcomes of intravitreal aflibercept in a Swiss routine treat and extend regimen for patients with neovascular age-related macular degeneration</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>The aim of this observational study was to assess the use and outcome of intravitreal aflibercept in a treat and extend regimen in treatment-naïve neovascular AMD patients in routine practice. This both retrospective and prospective study was conducted in four larger Swiss retina clinics (ASTERIA study). The primary endpoint was the mean change in best-corrected visual acuity (BCVA) in ETDRS letters from baseline to 12 months. Between December 2017 and August 2018, 160 patients were included. For patients with available data, the mean change in BCVA was + 8.4 (± 14.4) letters at month 12 (n = 139) and + 5.0 (± 11.4) letters at month 24 (n = 95). A mean number of 8.3 (± 2.4) injections were administered within the first year and 5.4 (± 2.9) injections during the second year. On average, the observed treatment interval at month 12 was 63.3 (± 22.0) days and increased to 69.1 (± 28.6) days at month 24. For 37% of the patients, a treatment interval ≥ 12 weeks was attained at month 24. In conclusion, intravitreal aflibercept in a Swiss real-life treat and extend regimen resulted in comparable anatomic and functional outcomes as were observed in the prospective registration trials of aflibercept for nAMD treatment.</description><subject>692/308/409</subject><subject>692/699/3161/1626</subject><subject>Acuity</subject><subject>Age</subject><subject>Angiogenesis Inhibitors - administration & dosage</subject><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>Clinical medicine</subject><subject>Clinical trials</subject><subject>Diabetic retinopathy</subject><subject>Disease</subject><subject>Ethics</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Intravitreal Injections</subject><subject>Macular degeneration</subject><subject>multidisciplinary</subject><subject>Observational studies</subject><subject>Receptors, Vascular Endothelial Growth Factor - administration & dosage</subject><subject>Receptors, Vascular Endothelial Growth Factor - therapeutic use</subject><subject>Recombinant Fusion Proteins - administration & dosage</subject><subject>Recombinant Fusion Proteins - therapeutic use</subject><subject>Registration</subject><subject>Retina</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><subject>Statistical analysis</subject><subject>Switzerland</subject><subject>Treatment Outcome</subject><subject>Visual Acuity</subject><subject>Wet Macular Degeneration - drug therapy</subject><subject>Wet Macular Degeneration - physiopathology</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9UU1v1TAQjBAVrdr-AQ7IEhcuAX_GyQUJVVCQKnFoOVuOs05dJfbDdt5r_wk_F7-mlNIDPngt78zsjqaqXhP8nmDWfkiciK6tMcW1bJjgNXlRHVHMRU0ZpS-fvA-r05RucDmCdpx0r6pDxijpKKdH1a-rXajvQEcUlmzCDAkFi5zPUW9djqAnpO3keogGNrk0kEaXO5cSioXgPKA9KCPtBwS3GUqJMLoZPLIhoo3ODnxOaOfyNfIQtjqZZSrj9Ah1hElnGNCs178BRvAQCyf4k-rA6inB6UM9rn58-Xx19rW--H7-7ezTRW245Llmg8Q9DKYdMEhGOgHMmrbVnHcdwYZaPvQMGykBWssIHhpr-wZ4uQQjkrPj6uOqu1n6uQjB3vqkNtHNOt6poJ36t-PdtRrDVsmmxQTjIvDuQSCGnwukrGaXDEyTLnaXpChvylzeYFGgb59Bb8ISfbFXUJIIKQTZb0RXlIkhpQj2cRmC1T57tWavSvbqPntFCunNUxuPlD9JFwBbAam0_Ajx7-z_yP4GFMe-UA</recordid><startdate>20201120</startdate><enddate>20201120</enddate><creator>Ebneter, Andreas</creator><creator>Michels, Stephan</creator><creator>Pruente, Christian</creator><creator>Imesch, Pascal</creator><creator>Eilenberger, Felix</creator><creator>Oesch, Susanne</creator><creator>Thomet-Hunziker, Isabelle P.</creator><creator>Hatz, Katja</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20201120</creationdate><title>Two-year outcomes of intravitreal aflibercept in a Swiss routine treat and extend regimen for patients with neovascular age-related macular degeneration</title><author>Ebneter, Andreas ; Michels, Stephan ; Pruente, Christian ; Imesch, Pascal ; Eilenberger, Felix ; Oesch, Susanne ; Thomet-Hunziker, Isabelle P. ; Hatz, Katja</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-3d70bedc8d0e73195e3fc88a449910c2f4db30c77ee8f310d6ffb6e4fb6531743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>692/308/409</topic><topic>692/699/3161/1626</topic><topic>Acuity</topic><topic>Age</topic><topic>Angiogenesis Inhibitors - administration & dosage</topic><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>Clinical medicine</topic><topic>Clinical trials</topic><topic>Diabetic retinopathy</topic><topic>Disease</topic><topic>Ethics</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Intravitreal Injections</topic><topic>Macular degeneration</topic><topic>multidisciplinary</topic><topic>Observational studies</topic><topic>Receptors, Vascular Endothelial Growth Factor - administration & dosage</topic><topic>Receptors, Vascular Endothelial Growth Factor - therapeutic use</topic><topic>Recombinant Fusion Proteins - administration & dosage</topic><topic>Recombinant Fusion Proteins - therapeutic use</topic><topic>Registration</topic><topic>Retina</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><topic>Statistical analysis</topic><topic>Switzerland</topic><topic>Treatment Outcome</topic><topic>Visual Acuity</topic><topic>Wet Macular Degeneration - drug therapy</topic><topic>Wet Macular Degeneration - physiopathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ebneter, Andreas</creatorcontrib><creatorcontrib>Michels, Stephan</creatorcontrib><creatorcontrib>Pruente, Christian</creatorcontrib><creatorcontrib>Imesch, Pascal</creatorcontrib><creatorcontrib>Eilenberger, Felix</creatorcontrib><creatorcontrib>Oesch, Susanne</creatorcontrib><creatorcontrib>Thomet-Hunziker, Isabelle P.</creatorcontrib><creatorcontrib>Hatz, Katja</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ebneter, Andreas</au><au>Michels, Stephan</au><au>Pruente, Christian</au><au>Imesch, Pascal</au><au>Eilenberger, Felix</au><au>Oesch, Susanne</au><au>Thomet-Hunziker, Isabelle P.</au><au>Hatz, Katja</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Two-year outcomes of intravitreal aflibercept in a Swiss routine treat and extend regimen for patients with neovascular age-related macular degeneration</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2020-11-20</date><risdate>2020</risdate><volume>10</volume><issue>1</issue><spage>20256</spage><epage>20256</epage><pages>20256-20256</pages><artnum>20256</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>The aim of this observational study was to assess the use and outcome of intravitreal aflibercept in a treat and extend regimen in treatment-naïve neovascular AMD patients in routine practice. This both retrospective and prospective study was conducted in four larger Swiss retina clinics (ASTERIA study). The primary endpoint was the mean change in best-corrected visual acuity (BCVA) in ETDRS letters from baseline to 12 months. Between December 2017 and August 2018, 160 patients were included. For patients with available data, the mean change in BCVA was + 8.4 (± 14.4) letters at month 12 (n = 139) and + 5.0 (± 11.4) letters at month 24 (n = 95). A mean number of 8.3 (± 2.4) injections were administered within the first year and 5.4 (± 2.9) injections during the second year. On average, the observed treatment interval at month 12 was 63.3 (± 22.0) days and increased to 69.1 (± 28.6) days at month 24. For 37% of the patients, a treatment interval ≥ 12 weeks was attained at month 24. In conclusion, intravitreal aflibercept in a Swiss real-life treat and extend regimen resulted in comparable anatomic and functional outcomes as were observed in the prospective registration trials of aflibercept for nAMD treatment.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>33219242</pmid><doi>10.1038/s41598-020-76354-1</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2045-2322 |
| ispartof | Scientific reports, 2020-11, Vol.10 (1), p.20256-20256, Article 20256 |
| issn | 2045-2322 2045-2322 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7680100 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Springer Nature OA Free Journals; Nature Free; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection; Free Full-Text Journals in Chemistry |
| subjects | 692/308/409 692/699/3161/1626 Acuity Age Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - therapeutic use Clinical medicine Clinical trials Diabetic retinopathy Disease Ethics Humanities and Social Sciences Humans Intravitreal Injections Macular degeneration multidisciplinary Observational studies Receptors, Vascular Endothelial Growth Factor - administration & dosage Receptors, Vascular Endothelial Growth Factor - therapeutic use Recombinant Fusion Proteins - administration & dosage Recombinant Fusion Proteins - therapeutic use Registration Retina Science Science (multidisciplinary) Statistical analysis Switzerland Treatment Outcome Visual Acuity Wet Macular Degeneration - drug therapy Wet Macular Degeneration - physiopathology |
| title | Two-year outcomes of intravitreal aflibercept in a Swiss routine treat and extend regimen for patients with neovascular age-related macular degeneration |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T22%3A48%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Two-year%20outcomes%20of%20intravitreal%20aflibercept%20in%20a%20Swiss%20routine%20treat%20and%20extend%20regimen%20for%20patients%20with%20neovascular%20age-related%20macular%20degeneration&rft.jtitle=Scientific%20reports&rft.au=Ebneter,%20Andreas&rft.date=2020-11-20&rft.volume=10&rft.issue=1&rft.spage=20256&rft.epage=20256&rft.pages=20256-20256&rft.artnum=20256&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/s41598-020-76354-1&rft_dat=%3Cproquest_pubme%3E2471575514%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2471575514&rft_id=info:pmid/33219242&rfr_iscdi=true |